Evidence map›Paper›PMID 37908083›Full record

ArticleApplied spectroscopy2023

Application of Raman Spectroscopy to Dynamic Binding Capacity Analysis.

James W Beattie, Ruth C Rowland-Jones, Monika Farys, Hamish Bettany, David Hilton, Sergei G Kazarian, Bernadette Byrne

Open access · hybridAbstract read
In one paragraph

Article in Applied spectroscopy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

James W BeattieDepartment of Life Sciences, Imperial College London, London, UK.ORCID 0000-0003-4028-0150
Ruth C Rowland-JonesBiopharm Process Research, Medicine Development and Supply, GSK R&D, Stevenage, Hertfordshire, UK.
Monika FarysBiopharm Process Research, Medicine Development and Supply, GSK R&D, Stevenage, Hertfordshire, UK.
Hamish BettanyBiopharm Process Research, Medicine Development and Supply, GSK R&D, Stevenage, Hertfordshire, UK.ORCID 0009-0008-2411-4834
David HiltonBiopharm Process Research, Medicine Development and Supply, GSK R&D, Stevenage, Hertfordshire, UK.
Sergei G KazarianDepartment of Chemical Engineering, Imperial College London, London, UK.ORCID 0000-0003-1768-9134
Bernadette ByrneDepartment of Life Sciences, Imperial College London, London, UK.ORCID 0000-0001-9598-9832
University of Hertfordshire · GBImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein A affinity chromatography is a key step in isolation of biotherapeutics (BTs) containing fragment crystallizable regions, including monoclonal and bispecific antibodies. Dynamic binding capacity (DBC) analysis assesses how much BT will bind to a protein A column. DBC reduces with column usage, effectively reducing the amount of recovered product over time. Drug regulatory bodies mandate chromatography resin lifetime for BT isolation, through measurement of parameters including DBC, so this feature is carefully monitored in industrial purification pipelines. High-performance affinity chromatography (HPAC) is typically used to assess the concentration of BT, which when loaded to the column results in significant breakthrough of BT in the flowthrough. HPAC gives an accurate assessment of DBC and how this changes over time but only reports on protein concentration, requires calibration for each new BT analyzed, and can only be used offline. Here we utilized Raman spectroscopy and revealed that this approach is at least as effective as both HPAC and ultraviolet chromatogram methods at monitoring DBC of protein A resins. In addition to reporting on protein concentration, the chemical information in the Raman spectra provides information on aggregation status and protein structure, providing extra quality controls to industrial bioprocessing pipelines. In combination with partial least square (PLS) analysis, Raman spectroscopy can be used to determine the DBC of a BT without prior calibration. Here we performed Raman analysis offline in a 96-well plate format, however, it is feasible to perform this inline. This study demonstrates the power of Raman spectroscopy as a significantly improved approach to DBC monitoring in industrial pipelines.

Indexed as

ProteinsSpectrum Analysis, RamanCalibrationChromatography, AffinityStaphylococcal Protein AProteinsStaphylococcal Protein ABiotherapeuticdynamic binding capacityhigh-performance affinity chromatographyHPACmonoclonal antibodyprotein A affinity chromatographyRaman spectroscopy

Identifiers

PMID37908083
PMCPMC10683347
OpenAlexW4388133371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.